Novo Nordisk blamed its lower sales forecast on competition from copycat versions of its anti-obesity drugs in the United ... its blockbuster diabetes and weight-loss treatments Ozempic and ...

Other health companies see room for products and services that take advantage of the popularity of new weight-loss drugs, which some analysts forecast will have annual sales of $150 billion in the ...

Novo Nordisk A/S NVO slashed its 2025 sales forecast ... branded GLP-1 weight loss and diabetes treatments in the U.S. market due to competition from compounded versions of the drugs.

Even with 72% of the global market share ... Novo also scored an exclusive deal to be listed as the preferred weight-loss drug for coverage on CVS's (CVS) formulary. This caused Lilly's stock ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, cut its ...

Other health companies see room for products and services that take advantage of the popularity of new weight-loss drugs, which some analysts forecast will have annual sales of $150 billion in the ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, cut its annual sales forecast on ... to a shortage of the drugs.

Wellness Companies Eager to Avoid WeightWatchers' Fate Embrace Weight-Loss Drugs ... of new weight-loss drugs, which some analysts forecast will have annual sales of $150 billion in the next ...